| Literature DB >> 29719832 |
Tiina A Jokela1,2, Agnete S T Engelsen1,3, Agata Rybicka1, Fanny A Pelissier Vatter1, James C Garbe4, Masaru Miyano2, Crina Tiron5, Dan Ferariu5, Lars A Akslen3, Martha R Stampfer4, James B Lorens1,3, Mark A LaBarge2,3,4.
Abstract
The existence of rareEntities:
Keywords: AXL; MEMA; breast cancer; cKIT; drug resistance; epithelial plasticity; microenvironment
Year: 2018 PMID: 29719832 PMCID: PMC5913284 DOI: 10.3389/fcell.2018.00041
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
Figure 1Human mammary epithelial cells from different stages in a malignant progression series exhibit unique growth characteristics in normal- and tumor-like microenvironments. Immunofluorescence staining of (A–D) normal and (E,F) invasive breast cancer tissue sections. ECM components; (A,B,E) COL4 (red), COL1 (green), (C,F) pan-laminin (LAM, green) and (D) LAM5 (green) in (A–D) normal mammary gland tissue and (E,F) invasive breast cancer, were stained with (A–F) nuclei marker Hoechst (blue), (C,E,F) epithelial cell marker (EPCAM) or with (D) myoepithelial cell marker (K14, red). (G) Diagram of the 184-progression series derivation. (H) Single cell suspensions of 184, 184A1, and 184AA3 cells were embedded in matrigel- and COL1-3D gels, after 12 days cells were fixed and stained with luminal cell marker (K19, green) and myoepithelial cell marker (K14, red). Images are representative of three individual experiments. (A,C–F,H) Bars represent 50 μm and (B) 5 μm. (I) Gene expression of microenvironment related genes (RT2Profiler™ PCR array, Human Epithelial to mesenchymal transition EMT, Qiagen) in 184A1 and 184AA3 cells cultured on matrigel (control = 1) or on COL1. Data represent mean ± SE, from two (184A1) or three (184AA3) individual experiments, statistical significance was calculated by using student T-test (*p < 0.05, **p < 0.01).
Figure 2Non-sporadic induction of AXL and cKIT expression by combinatorial microenvironments. (A,B) Unsupervised hierarchical clustering of mRNA expression levels of genes in the 184 progression series corresponding the gene products that were printed on MEMA: (A) microenvironment proteins and (B) their known receptors. (C) mRNA expression level of AXL and cKIT in the184 progression. (D) Diagram of the MicroEnvironment MicroArray (MEMA) experimental design. MEMAs are printed on microscope slides coated with polyacrylamide (PA) gel. 228 unique extracellular microenvironments with 5–20 replicate spots are printed on one slide. Cells are cultured on the arrays and grown 48 h before fixing. AXL and cKIT are stained for immunofluorescence imaging, and image analysis is used to obtain single cell expression data in discrete microenvironment contexts. (E) Unsupervised hierarchical clustering of AXL expression z-scores as a function of microenvironment in the 184 progression series. Non-sporadic clustering of AXL expression by major ECM component of microenvironment was detected. (F) Scatter plot representation of AXL and cKIT expression in single cells, as a function of ECM components (LAM1, COL4, and COL1) in the 184 progression series.
Figure 3Visualizing the impact of microenvironment on higher-order cell phenotypes, including AXL and cKIT expression. (A) Table representing GLM analysis of expression of the AXL+/cKIT+ phenotype in different microenvironments and significant differences was detected in patterns of microenvironment-phenotype associations between comparisons of all progression stages. **p ≤ 0.01, ***p ≤ 0.001. (B–H) Dimension reduction and visualization of microenvironment-driven phenotypes with tSNE visualization. Each point represents a unique combinatorial microenvironment, and the distance between any two points reflects similarity of the cellular phenotype that is begotten by the microenvironment. The characteristics that were measured in cells to establish phenotype were: % of cells that are AXL+/cKIT+, mean AXL, and cKIT fluorescent intensity in subpopulation and in ungated population, cell count/spot, -eccentricity, -solidity. (B–D) Shows the composition of each microenvironment, where (B) shows distribution of the major ECMs, (C) shows the distribution of the soluble factors, and (D) shows the distribution of GAS6 among the major ECM. The major ECM is a key driver of microenvironment-imposed phenotypes. Even GAS6, the cognate ligand of AXL does itself impact the tSNE distributions. (E–H) Show how specific aspects of cell phenotype distribute with microenvionment: (E) cell number per spot, (F) AXL+/cKIT+-subpopulation size, (G) mean AXL intensity, and (H) mean cKIT intensity.
Effect of ECM on expression of AXL+/cKIT+-phenotype in 184AA3.
| COL1-COL4 | −1.64569 | <0.001 |
| COL1-LAM1 | 0.04385 | 0.0621 |
| COL1-LAM1/LAM5 | −0.37975 | <0.001 |
| COL4-LAM1 | 1.53714 | <0.001 |
| COL4-LAM1/LAM5 | 1.26594 | <0.001 |
| LAM1-LAM1/LAM5 | −0.2712 | <0.001 |
GLM analysis with Tuckey's post-hoc test.
p ≤ 0.001.
Figure 4Identification and in vivo validation of microenvironment factors that impose AXL and cKIT expression phenotypes in malignant breast cancer cells. (A) AXL+/cKIT+-184AA3 phenotype expression in MEMA experiments was analyzed by GLM, and the most significant (Tuckey's post-hoc test, p < 2e-16***) microenvironment supplemental factors combined with different ECM are presented in bar graph format. (B,C) Co-expression of OPN (cyan), and AXL (red) were determined by RNA in situ hybridization of normal human mammary gland tissue (B), and TNBC (C) specimens. Co-expression IL-8 (cyan), and AXL (red) in normal human mammary gland tissue (D), and TNBC (E) specimens. Scale bar represent 20 μm (B–E). Expression of COL6A3 in normal human mammary gland tissue (F), and TNBC (G) specimens were assayed by IHC-P. (F,G) Scale bar = 100 μm. Counterstaining by hematoxylin (B–G). (H) Volcano plot represent EMT related gene expression (RT2Profiler™ PCR array, Human Epithelial to mesenchymal transition EMT, Qiagen) in 184AA3 cell cultured (24 h) on COL1, with or without OPN, IL-8, or COL6A3 was compared to expression profile of 184AA3 cells on matrigel. Results represent mean of three individual experiments, and p-values are calculated by comparing each gene expression in each group with the matrigel group, ***≤0.001. (I) To study drug resistance, 184AA3 cells were cultured on COL1 coated dishes supplemented with or without COL6A3, and treated with 0.1 μM paclitaxel. Data represent EdU positive cells as a percentage of total cells compared to COL1 control culture. Results represent mean ± SD in 6 individual experiments, significance between COL1 and COL1+COL6A3, *p = 0.02. (J) To study impact of OPN and IL-8 on paclitaxel IC50 values (μg/ml), 184AA3 cells were cultured on COL1 with or without OPN or IL-8. Cells were treated with Paclitaxel (ranging from 0.001 to 1 μg/ml). Results represent mean ± SD in 3 individual experiments, significance between IC50 values, **p < 0.01.
EMT related gene expression profile (RT2Profiler™ PCR array, Human Epithelial to mesenchymal transition EMT, Qiagen) of 184AA3 cell cultured (24 h).
| CAMK2N1 | 0.59 | 0.59 | 0.53 | 0.55 |
| RGS2 | 0.68 | 0.57 | 0.71 | 0.56 |
| MAP1B | 0.68 | 0.63 | 0.74 | 1.53 |
| GEMIN2 | 0.69 | 0.94 | 1.00 | 0.90 |
| FGFBP1 | 0.69 | 0.79 | 0.77 | 1.18 |
| TGFB2 | 0.69 | 0.76 | 0.51 | 1.05 |
| ZEB2 | 0.70 | 0.96 | 1.38 | 1.45 |
| ESR1 | 0.72 | 1.36 | 1.91 | 2.28 |
| STEAP1 | 0.74 | 1.39 | 1.55 | 1.57 |
| NUDT13 | 0.75 | 0.95 | 1.03 | 0.61 |
| SNAI2 | 0.82 | 3.99 | 1.08 | 4.76 |
| PTP4A1 | 0.82 | 1.06 | 0.88 | 0.81 |
| EGFR | 0.88 | 0.97 | 1.08 | 1.07 |
| OCLN | 0.88 | 1.13 | 0.91 | 1.37 |
| SMAD2 | 0.89 | 1.09 | 1.23 | 1.03 |
| RAC1 | 0.89 | 1.04 | 1.06 | 1.12 |
| DSP | 0.91 | 1.34 | 1.32 | 1.29 |
| DESI1 | 0.91 | 0.98 | 1.01 | 0.97 |
| KRT19 | 0.93 | 1.01 | 1.40 | 1.87 |
| SPP1 | 0.93 | 1.08 | 0.84 | 0.70 |
| SNAI1 | 0.93 | 2.31 | 1.47 | 1.27 |
| PTK2 | 0.94 | 1.12 | 1.21 | 1.20 |
| GSK3B | 0.95 | 1.02 | 1.13 | 1.35 |
| KRT7 | 0.95 | 0.77 | 0.79 | 0.75 |
| NODAL | 0.97 | 1.37 | 2.54 | 1.41 |
| TGFB3 | 0.98 | 1.19 | 1.10 | 0.90 |
| VPS13A | 0.98 | 1.36 | 1.61 | 1.29 |
| IL1RN | 1.00 | 1.35 | 0.97 | 2.15 |
| TIMP1 | 1.00 | 1.26 | 1.13 | 1.25 |
| CAV2 | 1.00 | 1.08 | 1.16 | 1.16 |
| TSPAN13 | 1.02 | 1.16 | 1.31 | 1.16 |
| TMEFF1 | 1.02 | 1.15 | 1.30 | 1.78 |
| TCF3 | 1.05 | 1.21 | 1.00 | 1.05 |
| BMP7 | 1.11 | 2.29 | 1.73 | 1.40 |
| FZD7 | 1.12 | 1.34 | 1.30 | 1.48 |
| STAT3 | 1.12 | 1.26 | 1.10 | 1.20 |
| TWIST1 | 1.14 | 1.28 | 1.12 | 1.15 |
| CALD1 | 1.15 | 1.49 | 1.65 | 1.45 |
| ERBB3 | 1.21 | 1.20 | 1.36 | 1.45 |
| AHNAK | 1.22 | 1.32 | 1.47 | 1.45 |
| AKT1 | 1.23 | 1.06 | 1.17 | 0.96 |
| F11R | 1.24 | 1.19 | 1.22 | 1.19 |
| DSC2 | 1.25 | 1.73 | 1.93 | 2.20 |
| CTNNB1 | 1.25 | 1.40 | 1.38 | 1.41 |
| NOTCH1 | 1.27 | 1.56 | 1.33 | 1.17 |
| TCF4 | 1.28 | 1.57 | 2.90 | 2.08 |
| ILK | 1.29 | 1.24 | 1.62 | 1.57 |
| ZEB1 | 1.34 | 1.36 | 1.91 | 2.56 |
| CDH1 | 1.34 | 1.30 | 1.55 | 2.01 |
| ITGB1 | 1.36 | 1.94 | 2.00 | 2.65 |
| PLEK2 | 1.36 | 1.45 | 1.60 | 1.91 |
| MSN | 1.39 | 1.66 | 1.69 | 1.79 |
| ITGAV | 1.41 | 1.67 | 1.78 | 3.39 |
| COL1A2 | 1.43 | 1.89 | 3.17 | 2.57 |
| FOXC2 | 1.43 | 1.52 | 1.33 | 1.31 |
| TFPI2 | 1.43 | 1.14 | 1.49 | 1.60 |
| BMP2 | 1.45 | 1.11 | 1.85 | 2.37 |
| MST1R | 1.48 | 1.41 | 1.79 | 1.40 |
| JAG1 | 1.57 | 1.65 | 2.24 | 2.81 |
| BMP1 | 1.62 | 1.68 | 2.05 | 2.00 |
| SERPINE1 | 1.64 | 1.47 | 2.23 | 2.01 |
| TGFB1 | 1.69 | 1.52 | 1.76 | 1.57 |
| IGFBP4 | 1.75 | 1.33 | 1.75 | 1.12 |
| MMP3 | 1.79 | 1.74 | 3.39 | 3.08 |
| KRT14 | 1.84 | 3.18 | 3.03 | 1.82 |
| TMEM132A | 1.93 | 1.26 | 1.41 | 2.03 |
| COL5A2 | 2.00 | 2.38 | 2.87 | 3.32 |
| SNAI3 | 2.03 | 2.59 | 3.78 | 5.66 |
| VCAN | 2.07 | 4.23 | 3.75 | 5.33 |
| ITGA5 | 2.12 | 1.76 | 2.54 | 2.79 |
| GNG11 | 2.24 | 1.97 | 2.33 | 2.62 |
| SPARC | 2.28 | 1.84 | 3.07 | 2.80 |
| VIM | 2.53 | 3.84 | 3.83 | 4.84 |
| FN1 | 3.00 | 2.12 | 4.79 | 8.02 |
| WNT5A | 3.18 | 4.90 | 6.69 | 10.86 |
| MMP9 | 3.80 | 3.04 | 3.44 | 7.49 |
| MMP2 | 4.00 | 4.44 | 5.81 | 7.06 |
Fold expression presented in table were calculated using the formula 2.
Key resources table.
| Anti-CD117 (cKIT) | Biolegend | 313201 | |
| Anti-AXL (10c9) | BerGenBio, Bergen, Norway | N/A | |
| Cytokeratin 14 antibody | Thermo scientific | PA5-16722 | |
| Anti-Cytokeratin 19 | Abcam | AB7754 | |
| Anti-Collagen type IV | Merck millipore | MAB3326 | |
| Anti-Collagen I | Abcam | AB34710 | |
| Anti-Laminin-5 | Merck millipore | MAB19562 | |
| Anti-Laminin | Sigma-aldrich | L9393 | |
| Anti-human CD326 (EPCAM) | Biolegend | 34202 | |
| Anti-AXL (mAb: 1H12) | BerGenBio, Bergen, Norway | N/A | |
| Anti-COL6A3 | Novus biologicals | NBP-71566 | |
| The human FFPE-healthy mammary gland and breast cancer tissues | The Department of Pathology, Haukeland University Hospital, Bergen, Norway, and the University Hospital of Iasi, Iasi, Romania | N/A | |
| Bone morphogenetic protein 2/7 heterodimer (BMP-2/7) | R&D systems | 3229-BM/CF | 1 μg/ml, (Ye et al., |
| Bone morphogenetic protein 4 (BMP-4) | R&D systems | 113-BP/CF | 1 μg/ml, (Ye et al., |
| Carcinoembryonic antigen-related cell adhesion molecule 6 (CEACAM6) | R&D systems | 3934-CM-050 | 1 μg/ml, (Beauchemin and Arabzadeh, |
| Carcinoembryonic antigen-related cell adhesion molecule 8 (CEACAM8) | Abnova | H00001088-P01 | 1 μg/ml, (Beauchemin and Arabzadeh, |
| CD44 | R&D systems | 3660-cd | 1 μg/ml, (Karousou et al., |
| Collagen I (COL1) | Sigma-Aldrich | C8919 | 100 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Collagen IV (COL4) | Sigma-Aldrich | C5533 | 100 μg/ml, (Insua-Rodriguez and Oskarsson, |
| CollagenXXIIIA1 (COL23A1) | R&D systems | 4165-CL | 1 μg/ml, (Spivey et al., |
| CollagenVIα3 (COL6A3) | MyBiosource | MBS958856 | 1 μg/ml, (Karousou et al., |
| E-Cadherin (ECAD) | Sigma-Aldrich | E2278 | 1 μg/ml, (Yu and Elble, |
| Epidermal growth factor (EGF) | Sigma-Aldrich | E9644 | 1 μg/ml, (Voudouri et al., |
| Fibroblast growth factor basic (FGF-2) | R&D systems | 233-FB-025 | 1 μg/ml, (Zheng et al., |
| Fibronectin (FN1) | Sigma-Aldrich | f2518 | 100 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Growth arrest specific 6 (GAS-6) | R&D systems | 885-GS-050 | 1 μg/ml, (Mc Cormack et al., |
| Hepatocyte growth factor (HGF) | R&D systems | 294-HG-005 | 1 μg/ml, (Ho-Yen et al., |
| Hyaluronan HMW (HA) | R&D systems | GLR002 | 100 μg/ml, (Karousou et al., |
| Insulin like growth factor-1 (IGF1) | R&D systems | 291-Gi-250 | 1 μg/ml, (Voudouri et al., |
| Interferon- γ (IFN-γ) | Gibco | PHC4031 | 1 μg/ml, (Esquivel-Velazquez et al., |
| Interleucin-1β (IL-1β) | Biolegend | 579404 | 1 μg/ml, (Esquivel-Velazquez et al., |
| Interleucin-6 (IL-6) | Biolegend | 570804 | 1 μg/ml, (Esquivel-Velazquez et al., |
| Interleucin-8 (IL-8, CXCL8) | Biolegend | 574204 | 1 μg/ml, (Palacios-Arreola et al., |
| Laminin-111 (LAM1) | Sigma-Aldrich | I2020 | 80 / 100 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Laminin-332 (LAM5) | Abcam | ab42326 | 20 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Leptin | Sigma-Aldrich | L4146 | 1 μg/ml, (Garcia-Robles et al., |
| Lumican | Sigma-Aldrich | 2846 | 1 μg/ml, (Nikitovic et al., |
| Melanoma growth stimulating activity alpha (GRO-α/CXCL1) | Sigma-Aldrich | G0657 | 1 μg/ml, (Palacios-Arreola et al., |
| Nidogen1 | R&D systems | 2570-nd | 1 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Osteopontin (OPN) | Novus Biologicals | NBC1-21056 | 1 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Osteoprotegerin (OPG) | R&D systems | 185-OS-025 | 1 μg/ml, (Weichhaus et al., |
| Stem cell factor (SCF) | R&D systems | 255-SC-010 | 1 μg/ml, (Mimeault et al., |
| Stromal derived factor-1 (SDF-1β/CXCL12) | Abnova | P4470 | 1 μg/ml, (Palacios-Arreola et al., |
| Tenascin C (TNC) | Chemicon | CC065 | 1 μg/ml, (Insua-Rodriguez and Oskarsson, |
| Tumor growth factor β (TGFβ) | Biolegend | 580704 | 1 μg/ml, (Esquivel-Velazquez et al., |
| Paclitaxel | Sigma-Aldrich | T7191 | |
| rat tail Collagen type I | Ibidi | 50201 | |
| Collagen type 1, calf skin | Sigma-Aldrich | C8919 | |
| Matrigel, growth factor reduced | Corning | 356231 | |
| RT2Profiler™ PCR arrays, human stem cell | Qiagen | PAHS-405ZF | |
| RT2Profiler™ PCR arrays, human epithelial to mesenchymal transition (EMT) | Qiagen | PAHS-090ZF | |
| Click-iT® Plus Edu imaging kit | Molecular probes | C10337 | |
| RT2 SYBR Green PCR Master Mix | Qiagen | 330503 | |
| RT2-First Strand Kit | Qiagen | 330401 | |
| Quick-RNA MicroPrep | Zymo Research | R1050 | |
| CellTiter-Glo 2.0 Assay | Promega | G9242 | |
| HMEC progression series | Dr. Martha Stampfer, Lawrence Berkeley national Laboratory, CA, USA | 184 | |
| RNAScope probe for | Advanced cell diagnostics | Probe-Hs-AXL-C2 | |
| RNAScope probe for | Advanced cell diagnostics | Probe-Hs-IL8-C1 | |
| RNAScope probe for | Advanced cell diagnostics | Probe-Hs-SPP1-C1 | |
| Cell profiler | |||
| R-language, R-studio | |||
| Cytobank | |||
| IC50 toolkit | |||